The companies collaborated to conduct the P-I/IIa clinical trial evaluating the safety, tolerability & preliminary efficacy of RC88 or RC108 combined with sintilimab in cancer patients
Innovent will lead the clinical drug supplies of sintilimab. RC88 monotx. exhibits anti-tumor activity in preliminary studies against MSLN-expressing solid tumors and demonstrated manageable safety while RC108 induces tumor-specific adaptive immunity in preclinical research, and enhances T-cell infiltration in the tumor microenvironment
RC88 with ICIs i.e., PD-1/PD-L1 can induce ICD releasing a series of signaling molecules that activate T cells & improve the tumor immune response
Ref: PRNewswire | Image: RemeGen
Related News:- Innovent and Eli Lilly Receive the NMPA’s Approval of Tyvyt (sintilimab) sNDA for EGFR-Mutated Non-Squamous NSCLC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
